Cellogen Therapeutics awaits CDSCO approval for Phase I trials on innovative CAR-T product targeting B cell leukemia.

A new artificial intelligence tool could help doctors determine which prostate cancer patients are most likely to benefit ...

A new study by LMU and Helmholtz Munich shows how the pathogen Trypanosoma brucei controls changes in its cell surface to evade the immune ...

Discover how the ALA-CART platform enhances CAR T cell efficacy against antigen-low leukemias. With improved LAT activation, ...

The immune system responds to an infection by producing antibodies that recognize and bind to the cell surface of the pathogen, thus marking it as an intruder and triggering an immune response. For ...

Antigenic variation is a key mechanism by which pathogens evade the immune system. New research has shown how trypanosomes ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.

The following is a summary of “Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients ...

Researchers at the Friedrich Loeffler Institute and the University of Greifswald in Germany have gained new insights into how the African swine fever (ASF) virus infiltrates the immune system of ...